289 related articles for article (PubMed ID: 29061745)
21. Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine.
Armitage EG; Alqaisi AQI; Godzien J; Peña I; Mbekeani AJ; Alonso-Herranz V; López-Gonzálvez Á; Martín J; Gabarro R; Denny PW; Barrett MP; Barbas C
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463533
[TBL] [Abstract][Full Text] [Related]
22. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM
Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336
[TBL] [Abstract][Full Text] [Related]
23. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.
Pérez-Victoria FJ; Castanys S; Gamarro F
Antimicrob Agents Chemother; 2003 Aug; 47(8):2397-403. PubMed ID: 12878496
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
Bhalla P; Sultana S; Chiranjivi AK; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133553
[TBL] [Abstract][Full Text] [Related]
25. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
26. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
[TBL] [Abstract][Full Text] [Related]
27. Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Das M; Saha G; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497
[TBL] [Abstract][Full Text] [Related]
28. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Imbert L; Ramos RG; Libong D; Abreu S; Loiseau PM; Chaminade P
Anal Bioanal Chem; 2012 Jan; 402(3):1169-82. PubMed ID: 22065347
[TBL] [Abstract][Full Text] [Related]
29. Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani.
Veronica J; Chandrasekaran S; Dayakar A; Devender M; Prajapati VK; Sundar S; Maurya R
FEBS J; 2019 Sep; 286(17):3488-3503. PubMed ID: 31087522
[TBL] [Abstract][Full Text] [Related]
30. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
31. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
32. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.
Paris C; Loiseau PM; Bories C; Bréard J
Antimicrob Agents Chemother; 2004 Mar; 48(3):852-9. PubMed ID: 14982775
[TBL] [Abstract][Full Text] [Related]
33. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Reimão JQ; Pita Pedro DP; Coelho AC
Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
[TBL] [Abstract][Full Text] [Related]
34. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
35. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
36. Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
Tegazzini D; Cantizani J; Peña I; Martín J; Coterón JM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005629. PubMed ID: 28542202
[TBL] [Abstract][Full Text] [Related]
37. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
38. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
Rakotomanga M; Blanc S; Gaudin K; Chaminade P; Loiseau PM
Antimicrob Agents Chemother; 2007 Apr; 51(4):1425-30. PubMed ID: 17242145
[TBL] [Abstract][Full Text] [Related]
39. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
Das S; Rani M; Pandey K; Sahoo GC; Rabidas VN; Singh D; Das P
J Antimicrob Chemother; 2012 Oct; 67(10):2373-8. PubMed ID: 22761329
[TBL] [Abstract][Full Text] [Related]
40. Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes.
Marinho Fde A; Gonçalves KC; Oliveira SS; Oliveira AC; Bellio M; d'Avila-Levy CM; Santos AL; Branquinha MH
Mem Inst Oswaldo Cruz; 2011 Jun; 106(4):507-9. PubMed ID: 21739043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
